(AQST) Aquestive Therapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(AQST) Aquestive Therapeutics, Inc. Complete Analysis Pack
Unlock Strategic Clarity
This Aquestive Therapeutics, Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio review. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Azstarys ADHD franchise
Azstarys is the clearest growth asset in Aquestive Therapeutics, Inc.'s mix because ADHD is a huge chronic market, with about 7.1 million U.S. children and 15.5 million adults diagnosed, per CDC latest estimates. Its once-daily dosing supports repeat use and better adherence, which helps scale in a condition that often needs long-term treatment. That gives Azstarys the profile of a true BCG "Star": high-growth category, branded pull, and room to take share.
Sympazan clobazam film
Sympazan clobazam film is a Star in Aquestive Therapeutics, Inc.'s BCG view: an oral soluble film for Lennox-Gastaut syndrome, a rare epilepsy affecting about 1 to 2 per 100,000 people. Demand can stay durable through 2025 because rescue and maintenance needs in orphan epilepsy remain high. Its film format gives clear differentiation in a specialty setting where ease of use matters.
KYNMOBI apomorphine film
KYNMOBI apomorphine film fits Stars because Parkinson’s disease affects about 1 million people in the U.S. and nearly 10 million worldwide, and episodic off periods remain a recurring need. Its sublingual film avoids injections and is a practical differentiator for fast rescue dosing. In a niche specialty market, that convenience can support premium pricing and attractive margins.
Oral film delivery platform
Oral film delivery platform is a Star because one dosage-form engine can support multiple molecules, so Cada new program can reuse the same formulation, manufacturing, and regulatory know-how. That repeatability lowers development friction and can speed launches in specialty pharma, where platform leverage often matters more than one-off products.
- Reusable know-how across molecules
- Lower development and scale-up risk
- Better leverage in specialty pharma
Partnered late-stage programs
Partnered late-stage programs can be a Star for Aquestive Therapeutics, Inc. because partners can fund development and speed launch, which matters in a market where FDA standard reviews often run about 10 months. External commercialization also cuts single-product concentration risk, so one approval can add revenue without Aquestive carrying the full go-to-market cost.
- Faster scale through partner sales teams
- Lower launch and concentration risk
- End-2025 upside needs approval and execution
That upside stays binary: if late-stage assets win approval and the partner executes well, the revenue step-up can be sharp; if not, the bucket stays a small BCG Star with high option value but no cash flow yet.
Aquestive’s Stars Shine in Niche Care With Platform Upside
Aquestive Therapeutics, Inc.'s Stars are Azstarys, Sympazan, KYNMOBI, and the oral film platform: they sit in high-need niches with repeat use, clear convenience gains, and share-taking upside. ADHD, rare epilepsy, and Parkinson's off periods all support durable demand, while the film platform can scale across molecules.
Partnered late-stage programs add optionality, since external funding can speed launch and limit cash burn.
| Star | Why it fits |
|---|---|
| Azstarys | ADHD scale, once-daily use |
| Sympazan/KYNMOBI | Oral film edge in niche care |
What is included in the product
Detailed Word Document
Aquestive Therapeutics’ BCG Matrix maps its pipeline and products by growth and market share to guide invest, hold, or divest decisions.
Editable Excel File
Quick BCG snapshot for Aquestive Therapeutics, Inc. to pinpoint growth bets and trim portfolio clutter.
Reference Sources
Provides a credible source trail for Aquestive Therapeutics, helping decision-makers verify claims and act with confidence.
Cash Cows
Suboxone sublingual film
Suboxone sublingual film is Aquestive Therapeutics, Inc.'s most established buprenorphine-naloxone brand and the clear cash cow in the portfolio. Opioid dependence is a mature, recurring market, so demand stays steady even as growth slows. This franchise has driven the strongest cash-generation profile, with management citing a large, durable U.S. treatment base and continued refill volume.
Approved branded film base
Approved branded film base is a Cash Cow because it is already commercialized, so Aquestive Therapeutics, Inc. spends far less on launch and market education than it does on pipeline assets. Mature branded products usually carry steadier margins, and that cash can help fund corporate overhead and R&D. One approved product line can keep paying while new programs stay in development.
Royalty and license income
Royalty and license income is a cash cow for Aquestive Therapeutics, Inc. because it monetizes the oral-film platform with low capital needs and little commercial spend. That usually means better cash conversion than development-stage assets, since partner royalties and upfront license fees can flow through with lean overhead. For a BCG view, it is the most efficient way to turn IP into cash.
Supply and manufacturing agreements
Supply and manufacturing agreements give Aquestive Therapeutics, Inc. steadier cash flow than launch-driven product sales, because contracted production usually fills plant capacity and supports gross margin. For a small-cap specialty company, that matters: fixed costs are spread over more units, so each run can help EBITDA. These revenue streams are also less volatile than new-product launches, which makes them a useful Cash Cow in the BCG Matrix.
- Higher factory utilization can lift margins.
- Contract revenue is usually more predictable.
- Stabilizes cash for R&D and launches.
Legacy prescription base
Aquestive Therapeutics, Inc.'s legacy prescription base fits cash-cow logic: older approved products can keep generating sales even when growth is thin. In 2024, the company still relied on marketed products for recurring prescription demand, which matters more for cash flow than expansion. Stable scripts can fund R&D and new launches without needing big volume gains.
- Older products keep cash flowing
- Growth is limited, but stable
- Useful for funding new launches
- Classic cash-cow behavior
Suboxone Film Powers Aquestive’s Steady Cash Flow
Suboxone film is Aquestive Therapeutics, Inc.'s clearest Cash Cow: a mature, reimbursed opioid-use brand that keeps throwing off repeat prescriptions with low launch spend. Royalty, license, and supply income also fit Cash Cow logic because they monetize the platform with lean capital use and steadier cash conversion. These lines help fund R&D and overhead while growth stays modest.
| Cash Cow stream | Why it fits |
|---|---|
| Suboxone film | Recurring demand, mature market |
| Royalties and supply | Low capex, steadier cash flow |
Full Version Awaits
Aquestive Therapeutics, Inc. Reference Sources
You’re previewing the exact Aquestive Therapeutics, Inc. BCG Matrix report you’ll receive after purchase. The full document is included with no changes, no watermarks, and no demo content. Once purchased, it’s ready for immediate download, use, or sharing with your team. What you see here is the final file.
Dogs
Zuplenz ondansetron film
Zuplenz ondansetron film sits in a generic-heavy anti-nausea market, where low-cost ondansetron tablets, ODTs, and injectables crowd out price. Growth is limited, and share is hard to defend.
That weak demand profile makes Zuplenz a Dogs asset in Aquestive Therapeutics, Inc.'s BCG Matrix.
It is a small, low-growth, low-share contributor with little pricing power.
Exservan riluzole film
Exservan (riluzole film) sits in a small ALS market: about 5,000 new U.S. ALS diagnoses a year, with roughly 30,000 people living with the disease. That keeps uptake constrained, and a niche oral-film option does not usually scale fast. In BCG terms, it fits low-growth, low-share economics, so it reads as a Dog.
Small-volume legacy films
Small-volume legacy films stay in the Dogs box because older oral-film SKUs often sell in tiny lots and add little to Aquestive Therapeutics, Inc.'s growth. They still soak up regulatory, quality, and supply work, but the payoff is weak; the company's recent revenue has remained only in the tens of millions, which shows how hard these products are to scale. With low volume, even modest upgrade or reformulation costs are hard to recover.
Non-core international sales
Non-core international sales at Aquestive Therapeutics, Inc. fit the "Dog" box when local demand is fragmented and share stays small. In BCG terms, assets that do not clear a meaningful share threshold, often under 10%, usually add little to group growth and are better as keep-or-exit bets.
These channels also face higher route-to-market costs, slower partner control, and weak scale economics. If a market cannot build repeatable volume, the best move is often to prune it or sell it.
- Fragmented markets cap scale
- Small share limits cash impact
- Keep-or-exit fits low-return assets
Low-adoption branded remnants
These low-adoption branded remnants are classic BCG Dogs: weak traction, limited scale, and little sign of a rebound. For Aquestive Therapeutics, Inc., products in this bucket tend to drain sales effort without moving the revenue needle, so extra marketing usually just lifts spend, not demand. If a brand cannot build repeat use or meaningful share, it is better treated as a harvest or exit candidate than a growth bet.
- Weak demand, low share, poor scale.
- Marketing rarely fixes the core issue.
- Best fit: harvest, trim, or exit.
Zuplenz and Exservan Show Aquestive’s Dog-Box Legacy Weakness
Zuplenz, Exservan, and other legacy oral-film lines fit the Dogs box for Aquestive Therapeutics, Inc.: low share, slow growth, and weak pricing power. In ALS, about 5,000 new U.S. cases and roughly 30,000 people living with the disease still leave Exservan niche and small.
| Asset | Signal | Dog cue |
|---|---|---|
| Zuplenz | Generic-heavy nausea market | Low share, weak price |
| Exservan | ~5,000 new ALS cases/year | Niche demand, low scale |
Question Marks
Libervant diazepam film
Libervant diazepam film meets a real need: FDA approved it on Apr. 26, 2024 for seizure clusters in children ages 2 to 5, a small but high-need rescue market. Adoption now depends on regulatory follow-through, payer access, and launch execution, not just the science. Market share is still the key unknown, so it fits a Question Mark in Aquestive Therapeutics, Inc.'s BCG Matrix.
AQST-108 systemic epinephrine
AQST-108 systemic epinephrine fits the Question Mark bucket: it targets a high-need rescue use, but its novel route must still prove real-world adoption. As of 2025, Aquestive Therapeutics, Inc. still needs clear data on prescribing, patient uptake, and repeat use before this franchise can move toward Star status.
AQST-305 octreotide film
AQST-305 octreotide film fits the "Question Mark" box because acromegaly is a rare endocrine niche, with prevalence around 40 to 70 cases per million, so the market is real but small. Aquestive Therapeutics, Inc. has not yet shown commercial scale here, and late-stage demand remains unproven. The drug could win on convenience, but adoption risk is still high.
AQST-109 oral epinephrine
AQST-109 oral epinephrine sits in a large anaphylaxis market, where about 32 million Americans live with food allergy and epinephrine auto-injectors still dominate emergency care. If Aquestive Therapeutics, Inc. wins approval and adoption, oral dosing could change how patients treat sudden reactions. For now, it is a classic question mark: high upside, but no durable sales yet.
- Large unmet need in anaphylaxis
- Could shift emergency allergy care
- Still unproven until approval and uptake
Next-generation complex molecules
Aquestive Therapeutics, Inc.'s next-generation complex molecules fit a Question Mark: they are the main growth option set, but market share is still not established. These programs need more capital, clinical data, and regulatory wins before they can scale, so upside is real but not proven yet.
- High growth potential, low share
- Needs funding and trial success
- Regulatory approval is key
- Could move to Star if wins stack up
Quest Marks, Big Upside: AQST's Growth Bets Still Need Proof
Aquestive Therapeutics, Inc.'s Question Marks are still low-share, high-upside bets: Libervant, AQST-108, AQST-305, and AQST-109 all target clear unmet need, but each still needs approval, access, or adoption to prove scale.
Libervant’s FDA approval on Apr. 26, 2024 and AQST-109’s anaphylaxis angle give the biggest upside, while AQST-305 stays niche and AQST-108 is still early.
| Program | Status | Signal |
|---|---|---|
| Libervant | Approved | Market share unproven |
| AQST-109 | Pipeline | Large allergy market |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.